Related Experiment Videos
Caspofungin: new preparation. A last resort in invasive aspergillosis
Abstract:
(1) Invasive aspergillosis is rare. It usually occurs in immunocompromised patients and is fatal despite treatment in 40-90% of cases. The reference treatments are standard amphotericin B, liposomal amphotericin B, and itraconazole. (2) Caspofungin, an antifungal drug, is now approved in the Europe Union for the treatment of invasive aspergillosis, when reference drugs fail or are poorly tolerated. (3) In a non comparative trial in 69 patients, intravenous caspofungin infusion was at least partly effective: 40% of patients survived with few relapses for at least one year following treatment. A historical comparison also favours caspofungin therapy. (4) The safety profile of caspofungin is poorly documented. It includes local reactions at the injection site, systemic reactions linked to the infusion (especially due to histamine release) and hepatic disorders. (5) Caspofungin is known to interact with tacrolimus (lower tacrolimus concentrations), ciclosporin (increased caspofungin bioavailability) and rifampicin (reduced caspofungin bioavailability). (6) In practice, caspofungin is an acceptable option for the treatment of invasive aspergillosis when standard amphotericin B, liposomal amphotericin B, and itraconazole are ineffective or poorly tolerated. Its clinical assessment is limited and must be continued.
Insights
Caspofungin offers a viable treatment for invasive aspergillosis when standard therapies fail. This antifungal shows effectiveness and survival benefits, though its safety and interactions require careful monitoring.
Area of Science:
- Mycology
- Infectious Diseases
- Clinical Pharmacology
Background:
- Invasive aspergillosis is a severe, often fatal infection primarily affecting immunocompromised individuals.
- Standard treatments include amphotericin B formulations and itraconazole, but resistance and intolerance are concerns.
Purpose of the Study:
- To evaluate the efficacy and safety of caspofungin for invasive aspergillosis.
- To assess caspofungin as an alternative when primary treatments are ineffective or poorly tolerated.
Main Methods:
- A non-comparative trial involving 69 patients treated with intravenous caspofungin.
- Historical comparisons were used to evaluate treatment outcomes.
Main Results:
- Intravenous caspofungin demonstrated partial effectiveness, with a 40% survival rate at one year post-treatment and few relapses.
- Historical data suggests caspofungin therapy is favorable compared to previous treatments.
Conclusions:
- Caspofungin is an acceptable treatment option for invasive aspergillosis when first-line therapies fail or are not tolerated.
- Further clinical assessment is necessary due to limited safety data and known drug interactions (tacrolimus, cyclosporine, rifampicin).